Dodgers minor league pitcher Josh Ravin is suspended for PED use
Dodgers minor league pitcher Josh Ravin on Monday was suspended 80 games for violating baseball’s performance-enhancing drug policy.
Ravin tested positive for Growth Hormone Releasing Peptide 2.
Ravin, 28, broke his left forearm in a car accident in February and has been on the disabled list all season. He was not expected to be able to pitch until June.
“We are disappointed to hear that Josh has violated Major League Baseball’s Joint Drug Prevention and Treatment Program,” the team said in a statement. “The Dodgers fully support MLB’s policy toward eliminating performance enhancing substances from the sport and, as per the Joint Drug Program, we will have no further comment on this suspension.”
In a statement, Ravin said his positive test was caused by supplements he took after dealing with illnesses during spring training.
“During 2016 spring training, I came down with a severe case of intestinal flu and strep throat. I was put on antibiotics and lost a total of 20 pounds in less than seven days,” Ravin said in a statement. “To try and speed up my recovery, I took some supplements that I thought would help. Unfortunately, I was not as careful as I should have been and one of the supplements contained a banned substance.
“I later learned that the substance showed up in a regular drug test done of me during 2016 spring training. This has been a very painful lesson for me. I have always tried to avoid doing anything in violation of the system and I take full responsibility for the consequences of my actions and my bad judgment. So, I have decided to accept the suspension and continue my ultimate goal to be able to pitch again in the major leagues.”
Ravin posted a 6.75 earned-run average in nine outings for the Dodgers in 2015. Because he is on the big league disabled list, he qualified as the sixth major leaguer to receive a suspension for violating the league’s drug policy this season.
Are you a true-blue fan?
Get our Dodgers Dugout newsletter for insights, news and much more.
You may occasionally receive promotional content from the Los Angeles Times.